[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560223":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":42,"centralContacts":47,"locations":54,"responsibleParty":73,"collaborators":52,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":52,"enrollmentInfo":85,"targetDuration":52,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":56,"whyStopped":52,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Avistone Biotechnology Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Vebreltinib 150mg BID+PLB1004 80mg QD","EXPERIMENTAL","Subjects will receive Vebreltinib 150mg orally twice per day (BID) + PLB1004 80mg orally once per day (QD),21day cycles until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.",[13,14],"Drug: Vebreltinib","Drug: PLB1004",{"label":16,"type":17,"description":18,"interventionNames":19},"Osimertinib 80mg QD","ACTIVE_COMPARATOR","Subjects will receive Osimertinib 80mg orally once per day (QD),21day cycles until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.",[20],"Drug: Osimertinib",[22,30,36],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Vebreltinib","Subjects will receive Vebreltinib orally twice per day (BID).",[9],[28,29],"Bozitinib","PLB1001",{"type":23,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Osimertinib","Subjects will receive Osimertinib 80mg orally once per day (QD).",[16],[35],"AZD9291",{"type":23,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"PLB1004","Subjects will receive PLB1004 80mg orally once per day (QD).",[9],[41],"Andamertinib",[43],{"name":44,"affiliation":45,"role":46},"Yi long Wu, MD","Guangdong Provincial People's Hospital","PRINCIPAL_INVESTIGATOR",[48],{"name":49,"role":50,"phone":51,"phoneExt":52,"email":53},"Liang Lin","CONTACT","08-10-84148931",null,"linliang@avistonebio.com",[55],{"facility":45,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Guangzhou","Guangdong","510080","China","CN",{"type":63,"coordinates":64},"Point",[65,66],113.25,23.11667,{"lat":66,"lon":65},[69],{"name":70,"role":50,"phone":71,"phoneExt":52,"email":72},"Jinji Yang, MD","+86-20-83827812","yangjinji@gdph.org.cn",{"type":74,"investigatorFullName":52,"investigatorTitle":52,"investigatorAffiliation":52,"oldNameTitle":52,"oldOrganization":52},"SPONSOR","100560223","phase-2-vebreltinib-plus-plb1004-as-the-first-line-therapy-for-patients-with-egfrmmet-locally-advanced-or-metastatic-nsclc-100560223",false,"NCT06574347","Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+\u002FMET+ Locally Advanced or Metastatic NSCLC.","A Phase II Study of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+\u002FMET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer.","KYLIN-2","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign a written informed consent document.\n2. Aged at least 18 years old.\n3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\\~IV).\n4. Patients with previously untreated, EGFRm-positive (exon 19 deletion or L858R) and MET overexpression (IHC 3+) .\n5. At least one measurable lesion as defined by RECIST V1.1.\n6. ECOG performance status 0 to 1.\n\nExclusion Criteria:\n\n1. There are mutations of ALK or ROS1.\n2. Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.\n3. Pregnant or nursing women.","ALL","18 Years",{"count":86,"type":87},120,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+\u002FMET+ Locally Advanced or Metastatic NSCLC.",[93],"Non-Small-Cell Lung Cancer",[95,96,97,98,99,100],"NSCLC","Lung Cancer","MET Amplification","EGFR L858R","EGFR Exon 19 Deletion","EGFR","2025-05-20",{"date":103,"type":104},"2025-05-21","ACTUAL",{"date":106,"type":104},"2024-08-07",{"date":108,"type":87},"2027-07-31",{"name":5,"class":6},1]